5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: A phase I safety study of a vascular disrupting agent

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1776-1784

  McKeage, Mark J ^a   Fong, Peter ^b   Jeffery, Mark ^d   Baguley, Bruce C ^c   Kestell, Phil ^c   Ravic, Miroslav ^e   Jameson, Michael B ^f  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

^e Antisoma Research Ltd   (United Kingdom)

^f WAIKATO HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; BIOLOGICAL MARKER; CISPLATIN DERIVATIVE; TAXANE DERIVATIVE; VASCULAR TARGETING AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BLOOD PRESSURE; BLOOD VESSEL INJURY; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMOGRAPHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; KIDNEY CANCER; LUNG ADENOCARCINOMA; MALE; MELANOMA; NASOPHARYNX CANCER; NAUSEA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; SINUS BRADYCARDIA; SINUS TACHYCARDIA; SYNOVIAL SARCOMA; TASTE DISORDER; TUMOR BLOOD FLOW; UTERINE CERVIX CANCER; VISUAL DISORDER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HUMANS; INFUSIONS, INTRAVENOUS; LONG QT SYNDROME; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; TREATMENT OUTCOME; TREMOR; XANTHONES;

EID: 33645659565     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1939     Document Type: Article

References (43)

1. Kelland LR. Targeting established tumor vasculature: a novel approach to cancer treatment. Curr Cancer Ther Rev 2005;1:1-9.
2. Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004;10:96-100.
3. Hill SA, Williams KB, Denekamp J. Studies with a panel of tumours having a variable sensitivity to FAA, to investigate its mechanism of action. Int J Radiat Biol 1991;60:379-84.
4. Plowman J, Narayanan VL, Dykes D, et al. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. CancelTreat Rep 1986;70:631-5.
5. Smith GP, Calveley SB, Smith MJ, Baguley BC. Flavone acetic acid (NSC 347512) induces hemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol 1987;23:1209-11.
6. Kerr DJ, Kaye SB. Flavone acetic acid-preclinical and clinical activity. Eur J Cancer Clin Oncol 1989;25:1271-2.
7. Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004;90:906-10.
8. Thomsen LL, Baguley BC, Wilson WR. Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1992;31:151-5.
9. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid. Br J Cancer 1990;62:932-4.
10. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 1994;6:79-85.
11. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC, Denny WA. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 1991;34:217-22.
12. Ching LM, Joseph WR, Crosier KE, Baguley BC. Induction of tumor necrosis factor-α messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 1994;54:870-2.
13. Philpott M, Joseph WR, Crosier KE, Baguley BC, Ching LM. Production of tumour necrosis factor-α by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 1997;76:1586-91.
14. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-70.
15. Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630-2.
16. Wilson WR, Li AE, Cowan DS, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 1998;42:905-8.
17. Horsman MR, Murata R, Overgaard J. Improving conventional cancer therapy by targeting tumour vasculature. Br J Cancer 1999;80:90.
18. Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997;39:541-6.
19. Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52.
20. Wilson WR, Baguley BC. Combination of the antivascular agent DMXAA with radiation and chemotherapy. Int J Radiat Oncol Biol Phys 2000;46:706.
21. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 1994;29:373-7.
22. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4- acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998;78:439-45.
23. Pedley RB, Boden JA, Boden R, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996;56:3293-300.
24. Pedley RB, Sharma SK, Boxer GM, et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 1999;59:3998-4003.
25. Cao Z, Joseph WR, Browne WL, et al. Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1999;80:716-23.
26. Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res 2001;61:1948-56.
27. Rustin GJ, Bradley C, Galbraith S, et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003;88:1160-7.
28. Jameson MB, Thompson PI, Baguley BC, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-50.
29. Rewcastle GW, Kestell P, Baguley BC, Denny WA. Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. J Natl Cancer Inst 1990;82:528-9.
30. Van de Water A, Verheyen J, Xhonneux R, Reneman RS. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 1989;22:207-17.
31. Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC. Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta 2001;314:159-66.
32. Kety SS. The theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol Rev 1951;3:1-41.
33. Tofts PS, Berkowitz B, Schnall MD. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995;33:564-8.
34. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-9.
35. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979;8:7-20.
36. Freeman PR. The performance of the two-stage analysis of two treatment, two period crossover trials. Stat Med 1989;8:1421-32.
37. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22.
38. McKeage MJ, Kestell P, Denny WA, Baguley BC. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemother Pharmacol 1991;28:409-13.
39. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM. Stimulation of tumors to synthesize tumor necrosis factor-α in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 1999;59:633-8.
40. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
41. Maxwell RJ, Wilson J, Prise VE, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002;15:89-98.
42. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92:1599-610.
43. Galbraith SM, Rustin GJ, Lodge MA, et al. Effects of 5,6- dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40.